Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $29.00 at JPMorgan Chase & Co.

Sage Therapeutics (NASDAQ:SAGEFree Report) had its price objective lifted by JPMorgan Chase & Co. from $24.00 to $29.00 in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on SAGE. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sage Therapeutics in a report on Tuesday, December 12th. They set a hold rating and a $21.00 price objective on the stock. Royal Bank of Canada upped their price target on shares of Sage Therapeutics from $21.00 to $26.00 and gave the company a sector perform rating in a report on Thursday, February 15th. Morgan Stanley upped their price target on shares of Sage Therapeutics from $20.00 to $22.00 and gave the company an equal weight rating in a report on Wednesday, February 28th. HC Wainwright upped their price target on shares of Sage Therapeutics from $25.00 to $28.00 and gave the company a neutral rating in a report on Thursday, February 15th. Finally, StockNews.com raised shares of Sage Therapeutics from a sell rating to a hold rating in a report on Thursday, February 15th. Fifteen investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and a consensus target price of $41.00.

Get Our Latest Research Report on Sage Therapeutics

Sage Therapeutics Trading Down 0.4 %

Shares of SAGE stock opened at $18.62 on Tuesday. The business’s fifty day simple moving average is $22.98 and its 200-day simple moving average is $21.43. The company has a market cap of $1.12 billion, a PE ratio of -2.06 and a beta of 0.87. Sage Therapeutics has a 12-month low of $16.51 and a 12-month high of $59.99.

Sage Therapeutics (NASDAQ:SAGEGet Free Report) last issued its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.73. The business had revenue of $77.97 million for the quarter, compared to the consensus estimate of $60.15 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The business’s quarterly revenue was up 2621.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.47) earnings per share. On average, equities analysts forecast that Sage Therapeutics will post -6.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SAGE. MetLife Investment Management LLC purchased a new position in Sage Therapeutics in the 1st quarter worth approximately $34,000. CWM LLC lifted its position in shares of Sage Therapeutics by 274.2% during the 3rd quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 883 shares during the last quarter. KBC Group NV purchased a new stake in Sage Therapeutics in the fourth quarter valued at $28,000. China Universal Asset Management Co. Ltd. lifted its position in Sage Therapeutics by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 748 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Sage Therapeutics in the first quarter valued at $209,000. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics Company Profile

(Get Free Report)

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

Recommended Stories

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.